• Syed Sajid Hussain Shah Department of Paediatric Nephrology, the Children’s Hospital and the Institute of Child Health, Lahore
  • Farkhanda Hafeez Department of Paediatric Nephrology, the Children’s Hospital and the Institute of Child Health, Lahore


Background: The management of steroid resistant nephrotic syndrome (SRNS) is quite difficult in paediatric patients. Not only the remission is difficult but also these patients are at risk of progression to end stage renal disease (ESRD). The goal of treatment is either to achieve complete remission or even partial remission as it is the most important predictor of disease outcome. Methods: This study was conducted at The Children’s Hospital, Lahore from February 2014 to May 2015. The SRNS patients of either sex between ages of 1–12 years were included with histology showing mesangioproliferative glomerulonephritis (MesangioPGN), focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD). Patients were given different immunosuppressant drugs and steroid 30 mg/m2 alternate day therapy on case to case basis and kept on regular follow up to check for response and adverse effects. Results: Total of 105 patients included, 63 (60%) male and 42 (40%) female patients. The age ranges from 1.08 to 12 years, mean age of 6.53 years and SD of ±3.17. Tacrolimus was the most common drug used 43 (41%) patients followed by cyclosporine in 38 (36.2%) patients, while Mycophenolate mofetil (MMF) was prescribed in 21 (20%) patients. Complete response was in 96 (91.4%) initially while partial response was seen in 8 (7.6%) patients. On follow up, 92 (87.6%) patients showed complete response and partial response was in 5 (4.7%) patients. Cushingoid features and hypertrichosis were the most common adverse effect seen. Conclusion: Steroid resistant nephrotic syndrome can be managed well with various immunosuppressant drugs and steroids but treatment should be individualized according to clinical presentation, disease histology and cost/social factors.Keywords: Steroid Resistant Nephrotic Syndrome, cyclosporine, tacrolimus, immunosuppressant, outcome


Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362(9384):629–39.

Mishra K, Ramachandran S, Firdaus S, Rath B. The Impact of Pediatric Nephrotic Syndrome on Parents’ Health- Related Quality of Life and Family Functioning: An Assessment Made by the PedsQL 4.0 Family Impact Module. Saudi J Kidney Dis Transpl 2015;26(2):285–92.

Rachmadi D, Melani A, Monnens L. NPHS2 Gene Mutation and Polymorphisms in Indonesian Children with Steroid-Resistant Nephrotic Syndrome. Open J Pediatr 2015;5(1):27–33.

Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change Nephrotic syndrome: Report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997;8(5):769–76.

Ehrich JHH, Pape L, Schiffer M. Corticosteroid resistant Nephrotic syndrome with focal and segmental glomerulosclerosis: An update of treatment options for children. Paediatr Drugs 2008;10(1):9–22.

Gulati S, Sengupta D, Sharma RK, Sharma A, Gupta RK, Singh U, et al. Steroid resistant nephrotic syndrome – role of histopathology. Indian Pediatr 2006;43(1):55–60.

Tryggvason K, Pettersson E. Causes and consequences of proteinuria: the kidney filtration barrier and progressive renal failure. J Intern Med 2003;254(3):216–24.

Životić M, Bogdanović R, Peco-Antić A, Paripović D, Stajić N, Vještica J, et al. Glomerular nestin expression: possible predictor of outcome of focal segmental glomerulosclerosis in children. Pediatr Nephrol 2015;30(1):79–90.

Malaga-Dieguez L, Bouhassira D, Gipson D, Trachtman H. Novel Therapies for FSGS: Preclinical and Clinical Studies. Adv Chronic Kidney Dis 2015;22(2):e1–e6.

Habashy D, Hodson EM, Craig JC. Interventions for steroid-resistant nephrotic syndrome: a systematic review. Pediatr Nephrol 2003;18(9):906–12.

Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, et al. Rituximab in Children with Resistant Idiopathic Nephrotic Syndrome. J Am Soc Nephrol 2012;23(6):1117–24.

van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011;26(6):881–92.

Hafeez F, Ahmed TM, Anwar S. Efficacy of steroids, cyclosporine and cyclophosphamide in steroid resistant nephrotic syndrome. JCPSP 2005;15(6):329-32.

Bérard E, Broyer M, Dehennault M, Dumas R, Eckart P, Fischbach M, et al. Corticosensitive nephrotic syndrome (or nephrosis) in children. Therapeutic guideline proposed by the Pediatric Society of Nephrology. Nephrol Ther 2005;1(3):150–6.

Hodson EM, Craig JC. Therapies for steroid-resistant nephritic syndrome. Pediatr Nephrol 2008;23(9):1391–4.

Kari JA, Halawani M. Treatment of Steroid Resistant Nephrotic Syndrome in Children. Saudi J Kidney Dis Transpl 2010;21(3):484–7.

El-Husseini A, El-Basuony F, Mahmoud I, Sheashaa H, Sabry A, Hassan R, et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome. Nephrol Dial Transplant 2005;20(11):2433–8.

Ghiggeri GM, Catarsi P, Scolari F, Caridi G, Bertelli R, Carrea A, et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther 2004;26(9):1411–8.

Plank C, Kalb V, Hinkes B, Hildebrandt F, Gefeller O, Rascher W. Cyclosporin A is superior to cyclophosphamide in children with steroid-resistant nephrotic syndrome—a randomized controlled multicenter trial by the Arbeitsgemeinschaft für Pädiatrische Nephrologie. Pediatr Nephrol 2008;23(9):1483–93.

Ulinski T, Dubourg L, Saïd MH, Parchoux B, Ranchin B, Cochat P. Switch from cyclosporine A to mycophenolate mofetil in nephrotic children. Pediatr Nephrol 2005;20(4):482–5.

Hodson EM, Habashy D, Craig JC. Intervention for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2006;(2):CD003594.

Wu B, Mao J, Shen H, Fu H, Wang J, Liu A, et al. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing. Nephrology (Carlton) 2015;20(1):18–24.

Gulati S, Prasad N, Sharm RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008;23(3):910–13.

Gipson DS, Gibson K, Gipson PE, Watkins S, Moxey-Mims M. Therapeutic approach to FSGS in children. Pediatr Nephrol 2007;22(1):28–36.



Most read articles by the same author(s)